The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant chemotherapy in the real world: A study of 22,819 patients from the Japanese National Clinical Database-Breast Cancer Registry.
 
Naoki Niikura
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Nihon Medi-Physics; Novartis; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Nihon Medi-Physics; Sanofi
 
Ai Tomotaki
Research Funding - Chugai Pharma (Inst); Johnson & Johnson (Inst); Kaketsuken (Inst); Nipro Corporation (Inst); Novartis (Inst); Olympus (Inst); St. Jude Medical (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); W.L. Gore & Associates (Inst)
 
Hiroaki Miyata
No Relationships to Disclose
 
Takayuki Iwamoto
No Relationships to Disclose
 
Masaaki S. Kawai
No Relationships to Disclose
 
Keisei Anan
No Relationships to Disclose
 
Takayuki Kinoshita
No Relationships to Disclose
 
Shinobu Masuda
No Relationships to Disclose
 
Koichiro Tsugawa
No Relationships to Disclose
 
Yutaka Tokuda
Honoraria - AstraZeneca; Covidien; Daiichi Sankyo; Eisai; Fuji Pharma; GlaxoSmithKline; Kyowa Hakko Kirin; Meiji Seika Kaisha; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Novartis; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Novartis; Taiho Pharmaceutical; Takeda